Answers are grounded in this paper and cite their sources.
Background: Sickle cell disease (SCD) is a debilitating chronic disease that impacts millions of people worldwide and often requires high-cost intensive management. Pain and fatigue are common symptoms of SCD; however, the economic burden associated with these symptoms remains largely unknown. Objectives: This retrospective longitudinal cohort study evaluated the association between acute pain and fatigue with healthcare resource utilization (HCRU) and medical costs among patients with SCD in the United States. Methods: TriNetX Linked Network claims database and TriNetX Dataworks-USA electronic health record data were used to identify patients aged 12 years and older who were diagnosed with SCD between October 1, 2015, and June 21, 2024. Study cohorts included patients with acute pain, fatigue, or both. Multivariable regression models were used to estimate odds ratios for HCRU and incremental annual total costs (2023 US dollars) to payers for patients with SCD experiencing one or more of these symptoms compared with those without (controls). Results: Acute pain and fatigue in patients with SCD were associated with substantially higher inpatient, emergency department, outpatient, and pharmacy utilization, as well as significantly higher total healthcare costs. In 12-month regression-adjusted all-cause cost analysis, acute pain, fatigue, or both were associated with increases of $6108, $7500, and $7689, respectively, compared with controls (all P < .001). Beyond increased pain- and fatigue-specific costs, pain and fatigue were associated with other elevated medical costs, highlighting their potential wider impact in driving overall healthcare expenditures among patients with SCD. Discussion: Study findings demonstrate the substantial clinical and economic burden associated with acute pain and fatigue among patients with SCD in the United States. Conclusions: Fatigue and acute pain were associated with a greater likelihood of annual HCRU and higher costs among patients with SCD, highlighting the need for treatments that alleviate these symptoms and reduce the associated economic burden.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: